Agenus Inc.
NASDAQ:AGEN · NASDAQ Capital Market
-$0.01 today
Vol 0.87M · Avg 0.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.0%
avg 100.1%
ROIC
-34.5%
avg -169.1%
ROA
0.1%
avg -64.7%
Analysis
ROA is currently the strongest return metric at 0.1% versus its period average of -64.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Garo H. Armen | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | $1.21M | — | 73 | $360,892.00 | 0.87% |
Steven J. O'Day | Chief Medical Officer | $902,820.00 | — | 65 | $95,333.00 | 0.23% |
Austin Charette | Senior Director, Financial Reporting and Compliance & Principal Accounting Officer | — | — | 37 | $17,619.00 | 0.04% |
Kamel Djazouli | Head of Medical Affairs | — | — | — | — | — |
Stefanie Perna-Nacar | Chief Communications & Government Relations Officer | — | — | — | — | — |
Zack Armen | Vice President of Investor Relations & Corporate Development | — | — | — | $360,892.00 | 0.87% |
Robin G. Taylor | Chief Commercial Officer | — | — | — | — | — |
Tracy Mazza Clemente | Chief People Officer | — | — | — | — | — |
Craig Winter | Chief Information Officer | — | — | — | — | — |
Todd Jude Yancey | Member of Advisory Board & Chief Strategic Advisor | — | — | — | — | — |
Jennifer S. Buell | Director and President & Chief Executive Officer of MiNK Therapeutics | — | — | 51 | $300,000.00 | 0.72% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +15.9% | +13.9% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.9% over three years. Forward estimates point to Revenue at +13.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$335.63M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$262.32M
Fate Therapeutics, Inc.
NASDAQ:FATE
$231.37M
Turn Therapeutics Inc.
NASDAQ:TTRX
$174.62M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$150.19M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$137.20M
Seer, Inc.
NASDAQ:SEER
$94.84M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$70.59M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.15M
VistaGen Therapeutics, Inc.
VTGN
$22.74M
Who manages AGEN?
Agenus Inc. (AGEN) lists 11 active executives. The top listed executive is Austin Charette, Senior Director, Financial Reporting and Compliance & Principal Accounting Officer.
Are AGEN insiders buying or selling?
Recent insider activity shows net buying of $16.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.